New combo attack on breast cancer brain tumors
NCT ID NCT07396454
Summary
This study is testing whether combining precise brain radiation with two cancer drugs (anlotinib and a tubulin inhibitor) can better control breast cancer that has spread to the brain. It is for women with HER2-negative breast cancer who have brain metastases. The main goal is to see if this combination can delay the cancer's growth in the brain and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.